Abstract |
Thirty-eight patients with advanced or recurrent squamous cell carcinoma of the cervix no longer amenable to management with surgery and/or radiotherapy were given piperazinedione 9 mg/m2 intravenously every 3 weeks. Five (13%) experienced either complete or partial regression of disease, while 13 (34%) demonstrated stable disease. Responses were relatively short (median 3 months) with responders surviving significantly longer than nonresponders (median 20.3 months vs. 3.0 months, p = 0.01). Adverse effects consisted primarily of myelosuppression (61%) and nausea and vomiting (47%) and generally were mild to moderate and tolerable. The drug has minimal activity and tolerable adverse effects and could be considered for trials of combination chemotherapy in this disease.
|
Authors | J T Thigpen, J Blessing, H D Homesley, L L Adcock |
Journal | American journal of clinical oncology
(Am J Clin Oncol)
Vol. 6
Issue 4
Pg. 423-6
(Aug 1983)
ISSN: 0277-3732 [Print] United States |
PMID | 6688150
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antibiotics, Antineoplastic
- Piperazines
- 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione
|
Topics |
- Adult
- Aged
- Antibiotics, Antineoplastic
(adverse effects, therapeutic use)
- Carcinoma, Squamous Cell
(drug therapy)
- Drug Evaluation
- Female
- Humans
- Leukocyte Count
- Leukopenia
(chemically induced)
- Middle Aged
- Neoplasm Recurrence, Local
- Piperazines
(adverse effects, therapeutic use)
- Thrombocytopenia
(chemically induced)
- Uterine Cervical Neoplasms
(drug therapy)
|